The Big Health Care Conundrum: How To Sustainably Unlock The Value Of Diagnostics
Novo Holdings Panel Asks Diagnostics Industry Leaders How To Keep The Focus On Testing Post-Pandemic
Executive Summary
With COVID-19 a residual but still very real issue globally, Novo Holdings asked the big diagnostics question at a recent high-level roundtable: How can stakeholders capitalize on this moment of acute public awareness of diagnostics to improve adoption of tests and screening in the long term? The CEOs of Roche Diagnostics, GE Healthcare, Labcorp and Synlab, among others, gave their thoughts on how the system must change.
You may also be interested in...
Epic Sciences Talks Differentiation And Benefits Of Its DefineMBC Cancer Test
Epic Sciences spoke to Medtech Insight to discuss the development of its DefineMBC test for metastatic breast cancer.
MHRA Offers Medtechs Extra Transition Time For UK Regulatory System Compliance
26 June saw the release finally of the UK government’s official response to the MHRA’s 2021 consultation on its post-Brexit medical devices regulatory framework. The considered response, held up by political and internal timing issues, represents an implementation plan for reform of the system. Crucially it allows industry extra compliance time.
NICE: Real-World Evidence Revolution Will Drive UK’s Health Care Innovation
In its just-released real-world evidence framework, NICE assesses the role and value of data collected outside highly-controlled clinical studies in driving more innovation towards health care professionals.